Paige Prostate Detect

CE & FDA | Prostate | Amplifier Integrator | H&E

Amplifier Marketplace Pathology

Description of use

Paige Prostate Detect is offered and sold as part of the Paige Prostate Suite.

FDA Intended Use (USA): Assists in the detection of foci suspicious for cancer. After initial review by a pathologist, if suspicious tissue is detected, Paige indicates the location with the highest likelihood of having cancer. For use with images digitized with Philips Ultra Fast Scanner & visualized with Paige FullFocus. Paige Prostate Detect is an adjunctive and should not be used as the primary diagnosis.

CE-IVD Intended Use (EU): Assists in the detection of foci suspicious for cancer. If suspicious tissue is detected, it provides the location with the highest likelihood for cancer & a heatmap with areas for further review by a pathologist. For use with images digitized with Philips Ultra Fast & Leica AT2 scanners & visualized with Paige FullFocus.

How is the application integrated?

Application can be launched from Sectra's pathology image window: Yes
Results will be shown in Sectra's pathology image window: No

Ask your Sectra representative which version of the Sectra PACS is compatible with the highlighted integration standards.

Contact us

Referring articles

The below are peer-reviewed articles that have been submitted by the AI vendor to serve as scientific validation of the application.

Other applications by this vendor

Paige Breast
CE | H&E
Paige Breast is a digital diagnostic aid for assisting pathologists with detecting and classifying carcinoma and atypical lesions on H&E stained WSIs of breast tissue.
Paige Breast Lymph Node
CE | H&E
Paige Breast Lymph Node is designed to aid pathologists in the detection of metastases in breast lymph node, guiding pathologists to areas suspicious for metastases including ITCs and small challenging micromets to improve diagnostic confidence.
Paige Prostate Biomarker Panel
CE | H&E
Paige Prostate Biomarker Panel is comprised of four AI models used to identify biomarkers including Androgen Receptor (AR) amplification, TP53, RB1 and PTEN mutations, based on the assessment of H&E-stained primary and metastatic prostate samples.

Let’s talk

Are you interested in learning more? Please do not hesitate to get in touch with us at Sectra.

Contact us

The application content is provided by the respective AI vendors.